Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2025
0mins
Should l Buy VRTX?
Source: NASDAQ.COM
Company Overview: Vertex Pharmaceuticals, with a market cap of $118.7 billion, focuses on innovative therapies for cystic fibrosis and rare diseases, reporting a 15.7% revenue growth in Q4 to $2.91 billion, though adjusted EPS fell short of expectations.
Stock Performance and Analyst Ratings: Despite underperforming the broader market over the past year, VRTX has seen a positive outlook from analysts, with a consensus rating of "Moderate Buy" and a raised price target reflecting strong sales expectations in cystic fibrosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 448.620
Low
414.00
Averages
515.88
High
604.00
Current: 448.620
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
CRISPR Therapeutics: Financing and Future Prospects
- Financing Details: On March 16, CRISPR Therapeutics completed a private offering of convertible senior notes, raising $585.2 million for general corporate purposes, although this has led to a 12% decline in stock price over the past month.
- Financial Performance: The company generated only $3.5 million in revenue last year, with a net loss of $581.6 million, which increased from $366.3 million the previous year, indicating significant challenges in profitability.
- Market Potential: Despite the losses, CRISPR maintains a working capital of approximately $1.8 billion, and its approved gene-editing therapy, Casgevy, has the potential to generate more revenue, having brought in $116 million last year.
- Investment Outlook: With a market cap of around $4.6 billion, CRISPR presents a mid-cap stock worth considering despite risks, as its investments in multiple potential projects and financial resources could lead to significant future value.
See More
CRISPR Raises $600 Million, Stock Price Pressured
- Funding Details: CRISPR completed a private offering of convertible senior notes, raising net proceeds of $585.2 million, which, while intended for general corporate purposes, has diluted equity and contributed to a 12% decline in stock price over the past month.
- Financial Performance: Despite generating only $3.5 million in revenue last year and experiencing a net loss that widened from $366.3 million to $581.6 million, CRISPR's financial position remains strong with working capital around $1.8 billion, indicating resilience amid ongoing losses.
- Product Outlook: CRISPR's approved gene-editing therapy, Casgevy, generated $116 million in revenue last year, and although profits are shared with partner Vertex Pharmaceuticals, there is optimism for additional approvals that could enhance revenue streams in the future.
- Market Potential: With a market cap of approximately $4.6 billion, CRISPR, despite its risks, represents a mid-cap stock with significant upside potential due to its early-stage products and ample financial resources, making it a noteworthy investment consideration.
See More
CGUS Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGUS's 52-week low is $28.95 and high is $41.38, with the latest trade at $38.72, indicating cautious market sentiment regarding its future performance within this range.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights those experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market trends.
See More
CRISPR Therapeutics Faces Challenges and Opportunities Ahead
- Poor Drug Launch Performance: Despite CRISPR Therapeutics receiving approval for its first commercial drug, Casgevy, in 2023, the market performance has not significantly boosted the stock price, with total revenue plummeting to $3.5 million in 2025 from $37.3 million in 2024, indicating insufficient market acceptance.
- High Treatment Costs: Casgevy's treatment costs $2.2 million and its complex administration process complicates partnerships with insurers and qualified treatment centers, resulting in limited profits for CRISPR, which shares a 40%-60% revenue split with Vertex Pharmaceuticals, exacerbating financial pressures.
- Slow Clinical Progress: CRISPR Therapeutics has failed to achieve sufficient clinical progress over the past few years to impress investors, with occasional positive results but overall lacking breakthrough advancements, leading to a continued decline in stock price, with net loss per share worsening to $6.47 in 2025.
- Future Potential to Explore: Despite challenges, CRISPR Therapeutics has several promising candidates in its pipeline, such as CTX310 and SRSD107, which, if successfully advanced, could improve the company's market outlook over the next 5 to 10 years, attracting attention from investors with above-average risk tolerance.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
CRISPR Therapeutics: Financing and Future Prospects
- Financing Details: On March 16, CRISPR Therapeutics completed a private offering of convertible senior notes, raising $585.2 million for general corporate purposes, although this has led to a 12% decline in stock price over the past month.
- Financial Performance: The company generated only $3.5 million in revenue last year, with a net loss of $581.6 million, which increased from $366.3 million the previous year, indicating significant challenges in profitability.
- Market Potential: Despite the losses, CRISPR maintains a working capital of approximately $1.8 billion, and its approved gene-editing therapy, Casgevy, has the potential to generate more revenue, having brought in $116 million last year.
- Investment Outlook: With a market cap of around $4.6 billion, CRISPR presents a mid-cap stock worth considering despite risks, as its investments in multiple potential projects and financial resources could lead to significant future value.
See More
CRISPR Raises $600 Million, Stock Price Pressured
- Funding Details: CRISPR completed a private offering of convertible senior notes, raising net proceeds of $585.2 million, which, while intended for general corporate purposes, has diluted equity and contributed to a 12% decline in stock price over the past month.
- Financial Performance: Despite generating only $3.5 million in revenue last year and experiencing a net loss that widened from $366.3 million to $581.6 million, CRISPR's financial position remains strong with working capital around $1.8 billion, indicating resilience amid ongoing losses.
- Product Outlook: CRISPR's approved gene-editing therapy, Casgevy, generated $116 million in revenue last year, and although profits are shared with partner Vertex Pharmaceuticals, there is optimism for additional approvals that could enhance revenue streams in the future.
- Market Potential: With a market cap of approximately $4.6 billion, CRISPR, despite its risks, represents a mid-cap stock with significant upside potential due to its early-stage products and ample financial resources, making it a noteworthy investment consideration.
See More
CGUS Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGUS's 52-week low is $28.95 and high is $41.38, with the latest trade at $38.72, indicating cautious market sentiment regarding its future performance within this range.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights those experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market trends.
See More
CRISPR Therapeutics Faces Challenges and Opportunities Ahead
- Poor Drug Launch Performance: Despite CRISPR Therapeutics receiving approval for its first commercial drug, Casgevy, in 2023, the market performance has not significantly boosted the stock price, with total revenue plummeting to $3.5 million in 2025 from $37.3 million in 2024, indicating insufficient market acceptance.
- High Treatment Costs: Casgevy's treatment costs $2.2 million and its complex administration process complicates partnerships with insurers and qualified treatment centers, resulting in limited profits for CRISPR, which shares a 40%-60% revenue split with Vertex Pharmaceuticals, exacerbating financial pressures.
- Slow Clinical Progress: CRISPR Therapeutics has failed to achieve sufficient clinical progress over the past few years to impress investors, with occasional positive results but overall lacking breakthrough advancements, leading to a continued decline in stock price, with net loss per share worsening to $6.47 in 2025.
- Future Potential to Explore: Despite challenges, CRISPR Therapeutics has several promising candidates in its pipeline, such as CTX310 and SRSD107, which, if successfully advanced, could improve the company's market outlook over the next 5 to 10 years, attracting attention from investors with above-average risk tolerance.
See More
